Expression and dendritic trafficking of BDNF-6 splice variant are impaired in knock-in mice carrying human BDNF Val66Met polymorphism

Alessandra Mallei¹, PhD; Gabriele Baj², PhD; Alessandro Ieraci¹, PhD; Stefano Corna¹, PhD; Laura Musazzi¹, PhD; Francis S. Lee³, MD, PhD; Enrico Tongiorgi², PhD; Maurizio Popoli¹, PhD

1. Laboratory of Neuropsychopharmacology and Functional Neurogenomics - Dipartimento di Scienze Farmacologiche e Biomolecolari and Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy
2. Department of Life Sciences, BRAIN Centre for Neuroscience, University of Trieste, Trieste, Italy
3. Department of Psychiatry, Weill Cornell Medical College of Cornell University, New York, New York 10065, USA

Category: Regular research article

Running title: Defective BDNF-6 transcript in BDNF Val66Met mice
Address correspondence to:
Alessandra Mallei, PhD
Laboratory of Neuropsychopharmacology and Functional Neurogenomics Department of Pharmacological and Biomolecular Sciences, University of Milano
Via Balzaretti 9 - 20133 Milano (Italy)
phone: +39 02 5031 8377
fax: +39 02 5031 8278
email: alessandra.mallei@unimi.it

No. of words (Abstract): 247
No. of words (Article body): 4358
Number of figures: 5
Number of tables: 2
Suppl. Information: 0

© The Author 2015. Published by Oxford University Press on behalf of CINP.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Abstract

Background: The human Val66Met polymorphism in brain-derived neurotrophic factor (BDNF), a key factor in neuroplasticity, synaptic function and cognition, has been implicated in pathophysiology of neuropsychiatric and neurodegenerative disorders. BDNF is encoded by multiple transcripts with distinct regulation and localization, but the impact of the Val66Met polymorphism on BDNF regulation remains unclear.

Methods: In BDNF Val66Met knock-in mice, which recapitulate the phenotypic hallmarks of individuals carrying the BDNF<sup>Met</sup> allele, we measured expression levels, epigenetic changes at promoters, and dendritic trafficking of distinct BDNF transcripts, using quantitative PCR, chromatin immunoprecipitation (ChIP), and in situ hybridization.

Results: BDNF-4 and BDNF-6 transcripts were reduced in BDNF<sup>Met/Met</sup> mice, compared with BDNF<sup>Val/Val</sup> mice. Chromatin immunoprecipitations for acetyl-histone H3 (acH3), a marker of active gene transcription, and trimethyl-histone-H3-Lys27 (H3K27me3), a marker of gene repression, showed higher H3K27me3 binding to exons 5, 6 and 8 promoters, in BDNF<sup>Met/Met</sup>. The H3K27 methyltransferase EZH2 resulted to be involved in epigenetic regulation of BDNF expression, because in neuroblastoma cells BDNF expression was increased both by siRNA for EZH2 and incubation with DZNep, an inhibitor of EZH2. In situ hybridization for BDNF-2, BDNF-4 and BDNF-6 after pilocarpine treatment showed that BDNF-6 transcript was virtually absent from distal dendrites of CA1 and CA3 regions in BDNF<sup>Met/Met</sup> mice, while no changes were found for BDNF-2 and BDNF-4.

Conclusions: Impaired BDNF expression and dendritic targeting in BDNF<sup>Met/Met</sup> mice may contribute to reduced regulated secretion of BDNF at synapses, and be a specific correlate of pathology in individuals carrying the Met allele.

Keywords: BDNF; epigenetics; Val66Met polymorphism; histone; dendritic trafficking
Introduction

Brain-derived neurotrophic factor (BDNF) is a key factor in neuroplasticity, synaptic function and cognition. Due to its pleiotropic effects in the brain, BDNF has been implicated in cognitive functions as well as in pathogenesis of various neuropsychiatric and neurodegenerative disorders (Duman and Monteggia, 2006; Tardito et al., 2006; Castrén et al., 2007; Martinowich et al., 2007). In particular, the human G196A polymorphism in the BDNF gene, which leads to a substitution of valine with methionine at codon 66 in the prodomain, has been thoroughly investigated for genetic association with cognitive dysfunction, personality disorders, neuropsychiatric and neurodegenerative disorders (Egan et al., 2003; Hariri et al., 2003; see Fukumoto et al., 2010; Verhagen et al., 2010 for recent meta-analyses). However, although a number of studies found a significant correlation of the Val66Met polymorphism with select disorders, others were unable to replicate the findings. It has been suggested that these conflicting results may originate from confounding factors such as age, gender, environmental factors, sample size, ethnicity and phenotype assessment (Hong et al., 2011). In addition, it is likely that the complex genetic background present in human populations can contribute to this problem. The BDNF Val66Met knock-in mouse offers an opportunity to investigate the pathophysiological consequences of the presence of the polymorphism in a constant and reproducible genetic background (Chen et al., 2006). This knock-in mouse recapitulates the phenotypic hallmarks of the BDNF Val66Met human polymorphism. Indeed, both human and mice BDNF<sup>Met</sup> allele carriers show reduced hippocampal volume, cognitive deficits, increased anxiety-related behavior and impaired extinction of fear conditioning, a type of learning involved in phobias and posttraumatic stress disorder (Chen et al., 2006; Frielingsdorf et al., 2010; Soliman et al., 2010). It has been shown
that BDNF<sup>Met/Met</sup> mice display reduced regulated secretion of BDNF from hippocampal neurons, reduced dendritic arborization in hippocampal dentate gyrus (DG), and reduced NMDA receptor-dependent synaptic plasticity in hippocampus (Chen et al., 2006; Ninan et al., 2010). Moreover, the binding of BDNF transcript to the protein translin, required for mRNA export into dendrites, is disrupted by the presence of the Met mutation in the coding region of BDNF mRNA (Chiaruttini et al., 2009). Accordingly, we proposed a hypothesis for the BDNF Val66Met-associated memory deficits as a model of impaired dendritic mRNA trafficking (Baj et al., 2013a).

The <i>bdnf</i> rodent gene is composed of at least eight untranslated 5’ exons and one 3’ exon encoding the protein, and different transcript isoforms are expressed by splicing each of the non-coding exons to the coding exon (Aid et al., 2007; Fig. 1). The complex structure of the BDNF gene allows the distinct BDNF transcripts to be differentially modulated at subcellular locations, in specific brain regions and in response to distinct stimuli (Baj et al., 2013b; Musazzi et al., 2014). We have previously shown that BDNF mRNA variants are spatially segregated in response to neuronal activation within three subcellular compartments: the soma (BDNF variants 1, 3, 5, 7, 8, 9a), the proximal (BDNF 4) or the distal dendrites (BDNF 2, 6), thus behaving as a spatial code (Baj et al., 2011; Baj et al., 2013b). Moreover, we have also shown that BDNF-6 trafficking to dendrites is increased by physical exercise and chronic antidepressant treatments (Baj et al., 2012), suggesting a role for local increase of BDNF-6 mRNA at dendrites in the pro-adaptive effects of these two treatments. Of note, BDNF expression can also be altered by genetic and epigenetic regulations, including histone posttranslational modifications (Martínez-Levy and Cruz-Fuentes, 2014). Accordingly, here we investigated whether the Val66Met mutation differentially affects the expression levels, epigenetic regulation and dendritic trafficking of the different BDNF transcripts.
Methods

Animals.

Three-four month-old male $\text{BDNF}^{\text{Met/Met}}$ and $\text{BDNF}^{\text{Val/Val}}$ mice were used for all studies (Chen et al., 2006). Mice were kept at 20-22°C on a 12 h light/dark cycle (light on at 7 a.m.) with water and food available ad libitum. All animal handling and experimental procedures were performed in accordance with the European Community Council Directive 86/609/EEC and were approved by Italian legislation on animal experimentation (116/1992). All efforts were made to minimize animal distress and to reduce the numbers of animals used in this study.

RNA isolation and reverse-transcription.

Total RNA was extracted from hippocampus of $\text{BDNF}^{\text{Met/Met}}$ and $\text{BDNF}^{\text{Val/Val}}$ mice, using the RNeasy Lipid Tissue Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions, and then quantified by absorption at $A_{260\text{nm}}$ measured by UV spectrophotometry (NanoVue, GE Healthcare Europe GmbH, Milano, Italy). cDNA was synthesized from 1 μg of DNase-treated total RNA using a QuantiTect Reverse Transcription kit (Qiagen) following manufacturer’s directions.

Quantitative real-time PCR.

Quantitative real time PCR (qPCR) analysis of mRNA expression levels was performed on a 7900HT Fast PCR System (Applied Biosystems by Life Technologies Italia, Monza, Italy) by using specific primers (Table 1) and QuantiFast SYBR Green master mix (Qiagen). All primers were as shown previously (Ieraci et al., 2015). To measure the distinct BDNF transcripts we designed one specific forward primer for each 5’ exon and one common reverse primer in the 5’ BDNF coding sequence. To measure BDNF-2, BDNF-7, and total BDNF mRNA, both forward
and reverse primers were within the respective exon region. PCR cycling conditions were: 10 min at 95°C, 40 cycles of 15 s at 95°C, 1 min at 60°C. Data from qPCR were normalized on the mean of two reference genes (β-actin, and Gapdh). Analysis of melting curve verified the specificity of the PCR products. Relative amounts were determined using the comparative Cq method (Schmittgen and Livak, 2008).

**Chromatin immunoprecipitation assay.**

Total hippocampi of 15 BDNF<sup>Met/Met</sup> and 15 BDNF<sup>Val/Val</sup> mice were used. Hippocampal tissue was cut into 1 mm<sup>3</sup> cubes and fixed in 1% formaldehyde at room temperature for 15 min to cross-link protein to DNA. Reaction was stopped by adding glycine (125 mM final concentration) for 5 min. Tissue was homogenized in SDS nuclei lysis buffer [50 mM Tris, pH 8.1, 10 mM EDTA, 1% SDS (Weinmann et al., 2001)]. Shearing of chromatin was performed with 13 cycles (20 sec on, 40 sec off) in a Microson sonicator (Misonix Inc., Farmingdale, New York). Chromatin sonication sheared cross-linked DNA to the optimal size of 200-800 base pair in length. Then, 150 µl chromatin was diluted 1:10 in chromatin immunoprecipitation (ChIP) dilution buffer (16.7 mM Tris, pH 8.1, 1.2 mM EDTA, 167 mM NaCl, 1.1% Triton X-100, 0.01% SDS). ChIPs were performed by using the MagnaChIP kit (Merck Millipore, Vimodrone, Italy) following manufacturer’s instructions. Briefly, chromatin was immunoprecipitated at 4°C with 10 µg each of the following antibodies: anti-H3K27me3 (Merck Millipore, catalog # 07-449), anti-acetyl histone H3 (acH3, Merck Millipore, catalog # 06-599), or normal rabbit IgG as control antibody (MagnaChIP kit, Merck Millipore). One hundredth of the pre-immunoprecipitated diluted chromatin was saved as ‘input’ DNA for ChIP normalization. Immune complexes were sequentially washed with low salt immune buffer, high salt buffer, LiCl immune complex buffer, and Tris-EDTA buffer. Protein–DNA cross-links were reversed by
heating at 62°C for 2 hours. After proteinase K digestion, DNA was purified by spin filter columns (MagnaChIP kit, Merck Millipore). To quantify histone-associated gene promoters, immunoprecipitated DNA samples were subjected to qPCR, on a 7900HT Fast PCR System (Applied Biosystems), using gene-specific primers and QuantiFast SYBR Green (Qiagen). The primer sequences used were either de novo designed using Primer Express software (Applied Biosystems) or previously published elsewhere (Tsankova et al., 2006). PCR cycling conditions were: 10 min at 95°C, 40 cycles of 15 s at 95°C, 1 min at 60°C. DNA quantities were estimated from the quantification cycle (Cq) and then expressed as % of corresponding input to normalize for differences in ChIP sample aliquots before immunoprecipitation. Briefly, % input was calculated by \(100 \times 2^{(Cq_{\text{adjusted Input}} - Cq_{\text{enriched}})}\). Input DNA Cq was adjusted from 1% to 100% equivalent by subtracting 6.644 Cqs or \(\log_2 100\). Analysis of melting curve verified the specificity of the PCR products.

**Cell cultures, 3-deazaneplanocin A treatment, and short interference RNA transfection**

Mouse neuroblastoma N2A cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Euroclone, Pero Italy), containing 10% FBS (Euroclone) and 1% penicillin/streptomycin (Euroclone) at 37°C and 5% CO\(_2\). 3-deazaneplanocin A (DZNep) was purchased from Sequoia Research (Pangbourne, UK). DZNep was dissolved in distilled water and stored at -20°C.

For DZNep treatments, 2 \(\times\) 10\(^5\) cells were seeded in 6 multiwell plates 24 hours before the treatments. DZNep was added to cell cultures with a range of concentration (0.5; 1 and 2 μM) and cells were harvested 24 hours later. RNA was extracted and processed for qPCR analysis. For short interference RNA (siRNA) knock-down studies, N2A cells were transfected with EZH2 (GeneSolution siRNA 1027416, Qiagen) or scramble siRNA (Negative Control siRNA 1022076,
Qiagen) according to the optimized protocol for N2A Cells (Amaxa® Cell Line Nucleofector® Kit V, Lonza, Basel, Switzerland). Briefly, 1 x 10^5 cells were resuspended in 100 μl of Mouse NSC Nucleofector Solution containing 100 nM of siRNA and nucleofected using the Program T-024 on an Amaxa Nucleofector II (Lonza). Cells were harvested 24 and 48 hours after transfection, RNA was extracted and processed for qPCR analysis.

**Pilocarpine treatment**

In order to measure dendritic targeting of BDNF by in situ hybridization and BDNF-2, BDNF-4, BDNF-6 and total BDNF mRNA expression, BDNF^{Met/Met} and BDNF^{Val/Val} mice were treated with pilocarpine (150 mg/kg, i.p., Sigma-Aldrich) dissolved in 0.9% NaCl. To reduce peripheral cholinergic effects, mice were pre-treated with methylscopolamine (1 mg/kg, i.p., Sigma-Aldrich) dissolved in PBS 20 min before receiving pilocarpine. For in situ hybridization experiment, six hours after pilocarpine administration, mice were anaesthetized with ketamine (100 mg/kg, i.p., Sigma-Aldrich) and transcardially perfused with freshly made 4% paraformaldehyde (PFA, in PBS pH 7.3). The brains were then removed and kept in 4% PFA/20% sucrose (in PBS pH 7.3) at 4°C for at least 3 days before sectioning in 40 μm slices using a CO₂-freezing microtome (Leica Microsystems, Milano, Italy). For BDNF transcripts expression, the vehicle groups were treated in sequence with PBS (as vehicle for methylscopolamine) and after 20 min with saline (as vehicle for pilocarpine). Six hours after either vehicle or pilocarpine administration mice were sacrificed, hippocampus collected, RNA extracted and processed for qPCR analysis.
In situ hybridization

Five BDNF<sup>Met/Met</sup> and five BDNF<sup>Val/Val</sup> mice were used. In situ hybridization on free-floating 40 µm coronal brain sections cut at the level of dorsal hippocampus was performed as described previously (Tongiorgi et al., 1998, 2004). Specific probes against BDNF transcript containing the BDNF-2, BDNF-4 or BDNF-6 were prepared from exon 2 nt 318-586 (Accession #NM_001270631), exon 4 nt 703–901 (Accession #X67107), or exon 6 nt 279–573 (Accession #S71211) cloned in pBSKS vector as previously described (Chiaruttini et al. 2008) using the DIG-RNA labeling kit according to manufacturer’s instructions (Roche Diagnostics, Monza, Italy). Probe specificity for BDNF-2, BDNF-4, and BDNF-6 was previously demonstrated (Chiaruttini et al., 2008). Hybridization with antisense probe was performed at 57°C followed by high stringency washes with 0.01X sodium saline citrate buffer containing 0.1% Tween-20 (SSCT) at 62°C. In situ hybridizations on brain sections from BDNF<sup>Met/Met</sup> and BDNF<sup>Val/Val</sup> mice were conducted in parallel. To obtain reproducible and comparable results and avoid saturation of the reaction, alkaline phosphatase development was always performed for 5 h at room temperature. The use of non-radioactive in situ hybridization with digoxigenin labeled probes for semi-quantitative evaluation of the in situ staining has been previously validated to study localization of dendritic mRNAs in vivo (Steward et al., 1998; Tongiorgi et al., 2004). In the present study, no saline-injected mice were included because in our previous work (Chiaruttini et al., 2009) the BDNF<sup>Met/Met</sup> and the BDNF<sup>Val/Val</sup> mice differed in dendritic targeting of BDNF only following pilocarpine-induced neuronal activity, since in basal condition BDNF mRNA is proximally confined. In addition, we previously found no difference between saline-injected or naive animals regarding the distribution of total BDNF mRNA (Tongiorgi et al., 2004) or exon 1, 2C, 4 and 6 mRNAs (Chiaruttini et al, 2008).
Statistical analysis for ChIP and qPCR.

For chromatin immunoprecipitation data, the percent input values from each data set was used in two-tailed unpaired t-tests to determine statistical significance. For mRNA data, fold changes relative to respective control group (ΔΔCq method) was used in two-tailed unpaired t-tests (when two experimental groups were analyzed), in Kruskal-Wallis test followed by Dunn’ multiple comparison test (when more than two experimental groups were analyzed), or in 2-way ANOVA followed by Bonferroni’s multiple comparison test (when the effect of the independent factors treatment and genotype were considered) to determine statistical significance. For all analyses a value of P < 0.05 was considered statistically significant. Statistical analysis of the data was carried out using GraphPad Prism4 (GraphPad Software, San Diego, California).

Quantitative image analysis and statistics.

Non-radioactive in situ hybridization was analyzed with a Nikon E800 microscope (X20 and X60 magnification, Nikon, Tokio, Japan) and a CCD camera (DXM-1200, Nikon). Images were captured with a fixed illumination using a procedure described previously (Tongiorgi et al., 2004) and analyzed with the program ImageJ (Schneider et al., 2012). Student’s t-test was used for two-sample comparisons using the SigmaStat software (Systat Software, Chicago, Illinois).
Results

Expression of splice variants containing BDNF-4 and BDNF-6 is lower in BDNF<sup>Val/Val</sup> mice.

We assessed the levels of BDNF mRNAs containing distinct transcripts of non-coding exons (BDNF-1 to BDNF-8) and total BDNF mRNA (all transcripts containing the coding exon 9) in hippocampus of BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice. qPCR analysis showed lower level of BDNF-4 (-20.45% vs. BDNF<sup>Val/Val</sup>; $P < 0.01$) and BDNF-6 (-21.33% vs. BDNF<sup>Val/Val</sup>; $P < 0.05$; Fig. 2) in BDNF<sup>Met/Met</sup> mice, while no significant difference was observed for the other BDNF variants (Fig. 2). Interestingly, levels of total BDNF showed a trend toward reduction, although this was not statistically significant (-14.88%; $P = 0.054$; Fig. 2). BDNF-5 transcript levels were very low in both BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice, which did not allow a reliable measurement of these mRNAs (not shown).

Lys27 trimethylation of H3 histone at select BDNF promoters is higher in hippocampus of BDNF<sup>Met/Met</sup> mice.

To understand whether epigenetic changes are involved in BDNF expression in mice carrying the BDNF Val66Met polymorphism, we investigated the regulation of chromatin architecture at different BDNF promoters. To this aim, we used ChIP assay combined with qPCR to assess levels of acH3 and H3K27me3 at promoters of all non-coding BDNF transcripts (BDNF-1 to -8). AcH3 and H3K27me3 are known markers of transcriptional activation and repression, respectively (Tsankova et al., 2006). AcH3 was unchanged for all BDNF promoters (Table 2). Instead, we found significantly higher level of H3K27me3 at BDNF-5 ($P < 0.005$), BDNF-6 ($P < 0.005$) and BDNF-8 ($P < 0.05$) promoters in BDNF<sup>Met/Met</sup> compared to BDNF<sup>Val/Val</sup> mice (Table 2). These results show that reduced expression of BDNF-6 in BDNF<sup>Met/Met</sup> mice may be accounted for by a higher level of Lys27 trimethylation of H3 histone at select BDNF promoters.
for by this epigenetic change at corresponding promoter. No changes were found at BDNF-4 promoter, although expression of the corresponding transcript was reduced in BDNF\textsuperscript{Met/Met}.

**EZH2 modulates BDNF gene expression**

H3K27 di- and trimethylation, an epigenetic modification leading to chromatin condensation and transcriptional repression, is mediated by the multiprotein complex Polycomb Repressive Complex 2 (PRC2) (Pasini et al., 2004; Margueron and Reinberg, 2011). The minimum core components necessary for the catalytic activity in vitro are EZH2, EED and SUZ12, with EZH2 being the actual histone methyltransferase in K27 trimethylation (Laugesen and Helin, 2014). EZH2 has been involved in epigenetic reprogramming related with carcinogenesis (Chang and Hung, 2012; Deb et al., 2014). To understand whether EZH2 is able to modulate the transcription of either total BDNF mRNA or of BDNF-6 transcript, we selectively down-regulated EZH2 expression in vitro using siRNA. Nucleofection of EZH2 siRNA in N2A neuroblastoma cells resulted in about 79.10 ± 1.35% (P < 0.01) and 54.36 ± 3.37% (P < 0.05) EZH2 mRNA reduction after 24 and 48 hours, respectively (Fig. 3a). This reduction of EZH2 was accompanied by up-regulation of total BDNF of 54.10 ± 15.53% (P < 0.05) and 48.50 ± 13.18% (P < 0.01) after 24 and 48 hours respectively (Figure 3a). At the same time points the increase of BDNF-6 revealed a significant difference only after 48 hours (12.10 ± 3.95%; P < 0.05) (Fig. 3a).

To further confirm the role of EZH2 in the regulation of BDNF gene expression, N2A cells were treated with different concentrations of 3-Deazaneplanocin A (DZNep), which has been shown to deplete and inhibit EZH2 (Kikuchi et al., 2012). DZNep increased the expression of both total BDNF and BDNF-6, with the higher response observed at 1 μM (total BDNF: 77.50 ±
22.79% of Veh; BDNF-6: 34.70 ± 9.22% of Veh; P < 0.01) (Fig. 3b). Therefore, the present results show that EZH2 may modulate BDNF transcription through H3K27 methylation.

**BDNF-6 dendritic trafficking is impaired in hippocampus of BDNF<sup>Met/Met</sup> mice.**

The splice variants containing BDNF-2, BDNF-6, and to a lesser extent BDNF-4, are the main ones targeted to dendrites in hippocampal neurons upon activation (Baj et al., 2011, 2013b). We have previously shown that trafficking of total BDNF in dendrites upon pilocarpine treatment is abolished in CA1 and CA3 hippocampal areas of BDNF<sup>Met/Met</sup> mice (Chiaruttini et al., 2009). Therefore, in the present study we sought to assess whether pilocarpine-induced dendritic targeting of these mRNA variants was also reduced in BDNF<sup>Met/Met</sup> mice. We employed in-situ hybridization to measure intracellular BDNF-2, BDNF-4 and BDNF-6 mRNA after pilocarpine stimulation in CA1, CA3, and DG areas of hippocampus of both mouse genotypes, as done previously for total BDNF mRNA (Chiaruttini et al., 2009) (Fig. 4a-c). In-situ hybridization experiments were carried out at 6 h post-pilocarpine because BDNF mRNA targeting in CA3 is maximum at this time in rodents (Tongiorgi et al., 2004) and CA3 is the region where the deficit in BDNF mRNA targeting was maximum in BDNF<sup>Met/Met</sup> mice (Chiaruttini et al., 2009). Densitometric analysis of in situ labeling, to measure the labeling intensity at different distances from the cell body layer, showed no differences in BDNF-2 subcellular localization in all three areas of hippocampus in BDNF<sup>Met/Met</sup> mice with respect to BDNF<sup>Val/Val</sup> (Fig. 4a). However, for BDNF-4, a significant reduction was found in the stratum pyramidale of CA1 and CA3 (Fig. 4b) while no changes were found in the other laminas. BDNF-6 mRNA labeling was significantly reduced in BDNF<sup>Met/Met</sup> mice in the proximal and distal stratum radiatum of both CA1 and CA3 (Fig 4c). No difference in pilocarpine-induced BDNF-6 trafficking was found in DG
between the two genotypes. These results showed that the reduced trafficking of BDNF mRNA in hippocampal areas, previously found in BDNF<sup>Met/Met</sup> mice (Chiaruttini et al., 2009), is accounted for mostly if not exclusively by BDNF-6 containing splice variant.

Pilocarpine has been shown to induce BDNF mRNA expression (Poulsen et al., 2004; Baj et al., 2013b) and since defective dendritic trafficking of BDNF transcripts could be due in principle to changes in either the trafficking mechanism or expression or both, we also sought to investigate whether expression of BDNF-2, BDNF-4, BDNF-6 and total BDNF were altered by pilocarpine treatment, in both genotypes. We found that pilocarpine increased the expression of BDNF-2, BDNF-4, and total BDNF similarly in both BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice (Fig. 5a,b,d), but did not affect significantly the expression of BDNF-6 (Fig. 5c). Therefore, our present and previous results combined show that impaired trafficking of BDNF-6 in BDNF<sup>Met/Met</sup> mice is not due to reduced expression but to a selective defect in translocation.

**Discussion**

BDNF has been implicated in the pathophysiology of brain disorders as well as in the action of therapeutic drugs, particularly antidepressants. We have previously reported that different BDNF transcripts code for different neuronal localization of BDNF (Chiaruttini et al., 2008), and that BDNF-6 is the major BDNF transcript targeted to dendrites upon neuronal activation (Baj et al., 2011, 2013b). More recently, we have shown that physical exercise and chronic antidepressant treatments not only increase BDNF expression in rodent hippocampus but also enhance targeting of BDNF mRNA in hippocampal dendrites, and that this increased trafficking is accounted for by the BDNF-6 containing splice variant (Baj et al., 2012, Ieraci et al., 2015).

The results of the present work can be summarized as follows: (1) homozygous mice carrying the human BDNF Val66Met polymorphism of BDNF (BDNF<sup>Met/Met</sup>) display repressive epigenetic
changes (increased H3K27me3) at BDNF promoters 5, 6 and 8; (2) the repressive epigenetic change at BDNF-6 promoter is accompanied by reduced transcription of BDNF-6; (3) neuronal activation-induced trafficking of BDNF-6 is also impaired in BDNF^{Met/Met} mice. This impairment is not due to reduced BDNF-6 expression but to a defect in translocation.

In a recent genome-wide (ChIP-Seq) analysis we found differential epigenetic changes in a large number of gene promoters of BDNF^{Met/Met} vs. BDNF^{Val/Val} mice (Popoli, 2012; ms. in preparation). Here we show that the presence of the human polymorphism also induces epigenetic changes in the BDNF gene itself. In particular, we have found an increase of H3K27me3 level at the BDNF-6 promoter, consistent with the decrease of BDNF-6 transcript expression. Moreover, in cell cultures we have shown that RNA silencing or pharmacological inhibition of EZH2, the methyltransferase that induces histone H3 trimethylation of Lys 27, increased the expression of total BDNF and BDNF-6 transcripts. These results are in line with recent data showing that EZH2 increases the amount of H3K27me3 at BDNF promoters and decreases BDNF expression in endothelial cells and primary cortical neurons, indicating a possible common mechanism of BDNF regulation in different cell types (Qi et al., 2014; Mitić et al., 2015). The present results strongly suggest that increased H3K27me3 induces transcriptional repression of BDNF-6, although additional epigenetic changes may be involved.

We have measured expression of total BDNF in hippocampus of BDNF^{Met/Met} mice and found no significant changes (although a trend for reduction was found), in agreement with previous studies comparing BDNF^{Val/Met} and BDNF^{Met/Met} mice (Li et al., 2010; Yu et al., 2012). This lack of effect of the Val/Met polymorphism on total BDNF may suggest that the reduction in expression of BDNF-4 and BDNF-6 splice variants is not enough to reduce significantly the total expression of BDNF (including all splice variants). However, it is noteworthy that, although total BDNF mRNA was found unchanged in BDNF^{Met} allele carrier mice, BDNF protein
has been previously found significantly reduced in both BDNF\textsuperscript{Val/Met} and BDNF\textsuperscript{Met/Met} mice (Li et al., 2010; Bath et al., 2012; Yu et al., 2012).

In the present study (except for BDNF-6) we often found lack of correlation between expression levels of transcripts and epigenetic changes at corresponding promoters. For instance, we found lower expression of BDNF-4 in BDNF\textsuperscript{Met/Met} mice, although no changes were found in H3 histone modifications. Also, differently from BDNF-4 and BDNF-6, we found no changes in expression of BDNF-8 in BDNF\textsuperscript{Met/Met}, although this promoter showed increased K27 trimethylation of associated H3 histone. However, the level of expression of a gene is the combinatorial result of several epigenetic changes. It is not surprising to find a lack of correlation between a single histone mark at gene promoter and expression levels of the corresponding gene (see Tsankova et al., 2004). It is possible that additional epigenetic changes regulate transcription of BDNF-8, explaining why in this case there is no direct correspondence between increased H3K27 trimethylation and reduced transcription.

We have previously shown that dendritic targeting of total BDNF is defective in BDNF\textsuperscript{Met/Met} mice (Chiaruttini et al., 2009). Interestingly, as shown here, BDNF\textsuperscript{Met/Met} mice display a selective impairment of BDNF-6 targeting to dendrites in CA1 and CA3 hippocampal areas. Combined with our previous results, showing that increased BDNF dendritic trafficking induced by physical exercise and chronic antidepressants is accounted for by BDNF-6 (Baj et al., 2012), the present results suggest a crucial role for BDNF-6 in mediating some effects of the neurotrophin at synaptic location. It can be envisaged that defective dendritic targeting of BDNF mRNA in BDNF\textsuperscript{Met/Met} mice is mainly due to changes in BDNF-6. Of note, we found that at 6h post-pilocarpine treatment, BDNF-2 mRNA was not detectable in hippocampal laminas containing dendrites either in BDNF\textsuperscript{Val/Val} or in BDNF\textsuperscript{Met/Met} mice. This finding suggests that BDNF-2 mRNA targeting may have a different time-course with respect to BDNF-6.
The present findings add to the significance of the BDNF Val66Met knock-in mice as an interesting model that recapitulates several aspects of neuropsychiatric pathology (Frielingsdorf et al., 2010). Reduced expression and dendritic targeting of BDNF-6 could be a causal factor for reduced regulated release of BDNF at synapses, found in this knock-in mouse (Chen et al., 2006).

It is not known how the presence of the BDNF polymorphism may affect epigenetic regulation of BDNF transcription. At present, a likely explanation is that BDNF and other neurotrophins are capable of regulating their own transcription (Mallei et al., 2004; Wibrand et al. 2006; Yasuda et al., 2007). This regulation is selective for different BDNF transcripts, as we have shown previously (Musazzi et al., 2014). Reduced availability of BDNF at synapses may in turn contribute to reduced dendritic development and hippocampal volume, which are recognized features of BDNF Val66Met knock-in mice. This could be a distinct feature of pathology not only in mice but also in humans carrying the BDNF Val66Met polymorphism, that display reduced hippocampal volume (Frodl et al., 2007). In addition, because dendritic targeting of BDNF-6 is involved in the antidepressant mechanism (Baj et al., 2012), the impairment of this mechanism in BDNF<sup>Met/Met</sup> mice could be a reason for the lack of response to selective serotonin reuptake inhibitors in these mice (Chen et al., 2006; Bath et al., 2012).

It has been proposed that dysfunction in the glutamate system, including altered glutamate release/transmission, clearance and metabolism, has a central role in neuropsychiatric pathophysiology (Sanacora et al., 2012). BDNF has a crucial role in the regulation of transmission and plasticity at glutamate synapses, and BDNF<sup>Met/Met</sup> mice have been shown to have impaired synaptic plasticity in hippocampus (Ninan et al., 2010). Further studies are warranted to investigate the effects of BDNF-6 overexpression or silencing on synaptic function and behavior, as well as on the response to stress. It will also be interesting to assess
the behavioral and cellular/molecular effects of chronic antidepressants or physical exercise in Val66Met knock-in mice, seen the specific influence exerted by these environmental factors on BDNF-6 expression and targeting (Baj et al., 2012) and its ability to modify the number of dendritic branching in the distal portion of the dendritic arbor (Baj et al., 2011).

**Funding**

This work was supported by a grant MIUR (PRIN 2010N8PBAA) to MP and ET and is part of the collaborative consortium “Italian Network on BDNF” (InBDNF). GB fellowship is supported by Fondazione Kathleen Foreman Casali-Trieste, FRA-UniTS 2012 and Beneficentia Stiftung-Vaduz (Lichtenstein).

**Acknowledgements**

None.

**Statement of Interest**

None.
References


Figure Legends

**Figure 1.** Schematic representation of mouse BDNF (a) gene and (b) transcripts structure.

**Figure 2.** Reduced expression of BDNF transcripts in BDNF$^{Met/Met}$ mice. BDNF transcript expression levels were analyzed by qPCR. BDNF$^{Met/Met}$ showed lower levels of BDNF-4 and BDNF-6 compared to BDNF$^{Val/Val}$ mice. Expression levels were normalized to β-actin and Gapdh and expressed as % relative to BDNF$^{Val/Val}$ mice. Data are presented as mean ± SEM (n= 6 independent biological replicates). (Student’s t test, *P < 0.05, **P < 0.01).

**Figure 3.** Modulation of total BDNF and BDNF-6 expression by EZH2. (a) Knockdown of EZH2 in N2A cells reduced expression of EZH2 (left panel). Knockdown of EZH2 induced upregulation of total BDNF mRNA 24 and 48 hours after the nucleofection, and upregulation of BDNF-6 after 48 hours (central and right panels). Expression levels were normalized to β-actin and Gapdh and results were expressed as mean ± SEM (n= 5 independent biological replicates). *P < 0.05; **P < 0.01 compared to scramble siRNA (SCR) by Student’s t-test. (b) mRNA levels of total BDNF and BDNF-6 in N2A cells were increased after 24 hours of treatment with 3-deazaneplanocin A (DZNep) at 0.5; 1 and 2 μM. Expression levels were normalized to β-actin and Gapdh and results are expressed as mean ± SEM (n= 5-6 independent biological replicates). *P < 0.05; **P < 0.01 compared to vehicle (VEH) by Kruskal-Wallis test followed by Dunn’s multiple comparison test.

**Figure 4.** Reduced BDNF-6 dendritic targeting in BDNF$^{Met/Met}$ mice after pilocarpine treatment. High-magnification pictures of the in situ hybridization and densitometric analysis of dendrites at progressive distances from soma for: (a) BDNF2-mRNA, (b) BDNF-4 and (c) BDNF-6 mRNAs.
in mouse hippocampal CA1, CA3, and DG regions of BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice. Data are expressed as gray level of the staining; the distance is expressed in µm from the point of emergence of the apical dendrites from the soma (≈0 µm), and the bar represents the mean ± SEM (n = 5 independent biological replicates). (*P < 0.05; **P < 0.01). S.pyr, stratum pyramidale; p.rad, proximal radiatum; d.rad, distal radiatum; lac.mol, lacunosum molecular layer; s.luc, stratum lucidum; OML, outer molecular layer; MML, medial molecular layer; IML, inner molecular layer; s.gr, stratum granularis.

**Figure 5.** Expression of BDNF-6 is not altered by pilocarpine. (a) Pilocarpine treatment increased BDNF-2 expression levels in hippocampus of BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice (two-way ANOVA, treatment effect: F<sub>(1,19) = 13.83</sub>, P = 0.0015; genotype effect: F<sub>(1,19) = 0.02023</sub>, P = 0.8884; interaction: F<sub>(1,19) = 1.289e-005</sub>, P = 0.9972). (b) Pilocarpine treatment increased BDNF-4 expression levels in hippocampus of BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice (two-way ANOVA, treatment effect: F<sub>(1,18) = 11.31</sub>, P = 0.0035; genotype effect: F<sub>(1,18) = 0.0538</sub>, P = 0.8192; interaction: F<sub>(1,18) = 0.00645</sub>, P = 0.9369). Additional post-hoc analysis with Student’s t test confirmed lower BDNF-4 levels in BDNF<sup>Met/Met</sup> vs. BDNF<sup>Val/Val</sup> mice (P = 0.0325). (c) BDNF-6 expression levels were analyzed by qPCR in hippocampus of BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice. Treatment with pilocarpine did not modify BDNF-6 levels (two-way ANOVA, treatment effect: F<sub>(1,19) = 0.4259</sub>, P = 0.5218; genotype effect: F<sub>(1,19) = 1.870</sub>, P = 0.1874; interaction: F<sub>(1,19) = 0.1794</sub>, P = 0.6767). Additional post-hoc analysis with Student’s t test confirmed lower BDNF-6 levels in BDNF<sup>Met/Met</sup> vs. BDNF<sup>Val/Val</sup> mice (P = 0.0309). (d) Pilocarpine treatment increased total BDNF expression levels in hippocampus of BDNF<sup>Val/Val</sup> and BDNF<sup>Met/Met</sup> mice (two-way ANOVA, treatment effect: F<sub>(1,18) = 11.93</sub>, P = 0.0028; genotype effect: F<sub>(1,18) = 0.1005</sub>, P = 0.7548; interaction: F<sub>(1,18) = 0.1471</sub>, P = 0.7059). Expression levels were normalized to β-actin and
Gapdh and expressed as % relative to BDNF$^{\text{Val/Val}}$ control mice. Data are presented as mean ± SEM (n= 5-7 independent biological replicates). Two-way ANOVA [**P < 0.01 vehicle (Veh) groups vs. pilocarpine treated (Pilo) groups] followed by Bonferroni’s multiple comparison test (§P < 0.05 compared to respective vehicle group) or Student’s t test (¶P < 0.05 compared to BDNF$^{\text{Val/Val}}$ vehicle).
<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward</th>
<th>Reverse</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Real time PCR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BDNF-1&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CCTGCATCTGTTGGGAGAC</td>
<td>CGCCTTCATGCAACCGAAGTAT</td>
</tr>
<tr>
<td>BDNF-2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>ACCTTTTCCTCCTCTCGG</td>
<td>TGGATGAAGTACTACCACCTCGG</td>
</tr>
<tr>
<td>BDNF-3&lt;sup&gt;a&lt;/sup&gt;</td>
<td>TGAGACTGCGCTCCACTCCC</td>
<td>CGCCTTCATGCAACCGAAGTAT</td>
</tr>
<tr>
<td>BDNF-4&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CAGAGCAGCTGCTTGTATGTTT</td>
<td>CGCCTTCATGCAACCGAAGTAT</td>
</tr>
<tr>
<td>BDNF-6&lt;sup&gt;a&lt;/sup&gt;</td>
<td>ACAATGTGACTCCACTGCCGG</td>
<td>CGCCTTCATGCAACCGAAGTAT</td>
</tr>
<tr>
<td>BDNF-7&lt;sup&gt;a&lt;/sup&gt;</td>
<td>ACTTACAGGTTCAAGGTCACAAG</td>
<td>GGACAGAGGGTGCGGATACAG</td>
</tr>
<tr>
<td>BDNF-8&lt;sup&gt;a&lt;/sup&gt;</td>
<td>ATGACTGTGATCCCAGGAGAAA</td>
<td>CGCCTTCATGCAACCGAAGTAT</td>
</tr>
<tr>
<td><strong>Total BDNF</strong>&lt;sup&gt;a&lt;/sup&gt;</td>
<td>TCGTTCCTTTTCAGTGAGGAAA</td>
<td>TTGGTAAACGGCACAACAAAC</td>
</tr>
<tr>
<td>EZH2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CAACCCTGTGACCATCCACG</td>
<td>CGACATCCAGGAAGCGGT</td>
</tr>
<tr>
<td>β-actin&lt;sup&gt;a&lt;/sup&gt;</td>
<td>GCCAGAGCAGATACTCCTCCTTC</td>
<td>AGTGTGACGTGATACAC</td>
</tr>
<tr>
<td>Gapdh&lt;sup&gt;a&lt;/sup&gt;</td>
<td>CGTGCAGCTGAGGGAGAAC</td>
<td>TGGAAGAGTGAGGAGTGGTTC</td>
</tr>
<tr>
<td><strong>ChIP</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pBDNF-1&lt;sup&gt;b&lt;/sup&gt;</td>
<td>TGATCATCCTACTCAGCACCAG</td>
<td>CAGCCTCTCTGAGCCAGTAC</td>
</tr>
<tr>
<td>pBDNF-2&lt;sup&gt;b&lt;/sup&gt;</td>
<td>CGTCCTTGATTCCTCCCTCCTTG</td>
<td>CCCCAACCCACCACTACCCCT</td>
</tr>
<tr>
<td>pBDNF-3&lt;sup&gt;b&lt;/sup&gt;</td>
<td>GTGAGACCTGGGGCCAAATC</td>
<td>ACGGAAAAAGGAGGAGGAAA</td>
</tr>
<tr>
<td>pBDNF-4&lt;sup&gt;b&lt;/sup&gt;</td>
<td>CTTCTGTTGAGTGTTTGTATG</td>
<td>AGTCACAGGAGGCTCA</td>
</tr>
<tr>
<td>pBDNF-5&lt;sup&gt;b&lt;/sup&gt;</td>
<td>GCTGAAGCGGTGCAGATT</td>
<td>GGCCTATGTACCTCCTTGT</td>
</tr>
<tr>
<td>pBDNF-6&lt;sup&gt;b&lt;/sup&gt;</td>
<td>ACTCACACTCGCTCCTCCTCCT</td>
<td>GCACCTGCTCTTTCTCCTT</td>
</tr>
<tr>
<td>pBDNF-7&lt;sup&gt;b&lt;/sup&gt;</td>
<td>GGAAGGTTGGTGAGAGGATAGAG</td>
<td>GTGCTCAAGGCGGTGTAAG</td>
</tr>
<tr>
<td>pBDNF-8&lt;sup&gt;b&lt;/sup&gt;</td>
<td>TGAAGGAAAAGGAGGAGGCTTT</td>
<td>AGAAAATGCCACTCCCACATAAG</td>
</tr>
</tbody>
</table>

<sup>a</sup>Primer sequences as in Ieraci et al. (2015)

<sup>b</sup>Primer sequences as in Tsankova et al. (2006)
### Table 2. Levels of occupancy of acH3 and H3K27me3 at BDNF gene promoters

<table>
<thead>
<tr>
<th>Gene promoter</th>
<th>BDNF&lt;sup&gt;Val/Val&lt;/sup&gt;</th>
<th>BDNF&lt;sup&gt;Met/Met&lt;/sup&gt;</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>acH3</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pBDNF-1</td>
<td>0.430 ± 0.0996</td>
<td>0.572 ± 0.1044</td>
<td>0.3819</td>
</tr>
<tr>
<td>pBDNF-2</td>
<td>0.219 ± 0.0252</td>
<td>0.339 ± 0.0447</td>
<td>0.0799</td>
</tr>
<tr>
<td>pBDNF-3</td>
<td>0.442 ± 0.0834</td>
<td>0.697 ± 0.1766</td>
<td>0.2616</td>
</tr>
<tr>
<td>pBDNF-4</td>
<td>0.491 ± 0.0478</td>
<td>0.493 ± 0.0938</td>
<td>0.9858</td>
</tr>
<tr>
<td>pBDNF-5</td>
<td>0.517 ± 0.0668</td>
<td>0.673 ± 0.1110</td>
<td>0.2948</td>
</tr>
<tr>
<td>pBDNF-6</td>
<td>0.812 ± 0.0888</td>
<td>1.059 ± 0.0698</td>
<td>0.0946</td>
</tr>
<tr>
<td>pBDNF-7</td>
<td>0.874 ± 0.1258</td>
<td>1.118 ± 0.1974</td>
<td>0.3561</td>
</tr>
<tr>
<td>pBDNF-8</td>
<td>0.099 ± 0.0249</td>
<td>0.1323 ± 0.0313</td>
<td>0.4561</td>
</tr>
<tr>
<td><strong>H3K27me3</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pBDNF-1</td>
<td>3.250 ± 0.3227</td>
<td>3.717 ± 0.3250</td>
<td>0.3658</td>
</tr>
<tr>
<td>pBDNF-2</td>
<td>3.658 ± 0.1721</td>
<td>4.487 ± 0.3230</td>
<td>0.0861</td>
</tr>
<tr>
<td>pBDNF-3</td>
<td>3.555 ± 0.4545</td>
<td>4.374 ± 0.5488</td>
<td>0.3143</td>
</tr>
<tr>
<td>pBDNF-4</td>
<td>3.196 ± 0.2194</td>
<td>3.300 ± 0.4021</td>
<td>0.8321</td>
</tr>
<tr>
<td>pBDNF-5</td>
<td>2.421 ± 0.0428</td>
<td>3.156 ± 0.079</td>
<td>0.0012*</td>
</tr>
<tr>
<td>pBDNF-6</td>
<td>3.954 ± 0.0832</td>
<td>4.543 ± 0.0557</td>
<td>0.0042*</td>
</tr>
<tr>
<td>pBDNF-7</td>
<td>2.992 ± 0.1374</td>
<td>3.657 ± 0.574</td>
<td>0.0851</td>
</tr>
<tr>
<td>pBDNF-8</td>
<td>1.645 ± 0.1478</td>
<td>2.331 ± 0.079</td>
<td>0.0150*</td>
</tr>
</tbody>
</table>

Data are expressed as % of input and presented as mean ± SEM. (Student’s t test; *significant difference).
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.